Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $15.00 Consensus Price Target from Brokerages

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) has received a consensus rating of "Buy" from the eight brokerages that are covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $15.00.

A number of brokerages have recently commented on TNYA. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a research report on Wednesday, May 15th. Chardan Capital reiterated a "buy" rating and set a $20.00 target price on shares of Tenaya Therapeutics in a research report on Thursday, March 21st. William Blair started coverage on Tenaya Therapeutics in a research report on Monday, June 10th. They set an "outperform" rating on the stock. Finally, Canaccord Genuity Group reduced their target price on Tenaya Therapeutics from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Thursday, May 16th.

Tenaya Therapeutics Trading Up 8.1 %

Shares of NASDAQ TNYA traded up $0.22 during midday trading on Thursday, reaching $2.94. 1,252,840 shares of the stock were exchanged, compared to its average volume of 474,535. The stock has a 50 day moving average price of $4.04 and a 200-day moving average price of $4.27. The company has a market capitalization of $230.85 million, a P/E ratio of -1.77 and a beta of 2.52. Tenaya Therapeutics has a 52-week low of $1.66 and a 52-week high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.03. On average, analysts forecast that Tenaya Therapeutics will post -1.59 earnings per share for the current year.

Institutional Investors Weigh In On Tenaya Therapeutics

Large investors have recently made changes to their positions in the business. Redwood Wealth Management Group LLC increased its holdings in Tenaya Therapeutics by 38.0% in the 4th quarter. Redwood Wealth Management Group LLC now owns 16,350 shares of the company's stock valued at $53,000 after purchasing an additional 4,500 shares in the last quarter. SG Americas Securities LLC increased its holdings in Tenaya Therapeutics by 20.0% in the 4th quarter. SG Americas Securities LLC now owns 25,337 shares of the company's stock valued at $82,000 after purchasing an additional 4,224 shares in the last quarter. Bailard Inc. acquired a new stake in Tenaya Therapeutics in the 4th quarter valued at $107,000. NEOS Investment Management LLC acquired a new stake in Tenaya Therapeutics in the 4th quarter valued at $201,000. Finally, HighPoint Advisor Group LLC purchased a new position in Tenaya Therapeutics in the 4th quarter valued at about $228,000. Institutional investors and hedge funds own 90.54% of the company's stock.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.